MedWatch

A part of Watch Media

GN denies involvement in false advertising case

GN Hearing acquired US-based online platform Lively after the latter had stopped its misleading marketing, and did therefore not take part in the advertising slipup that led to a settlement in the US including payments to the state of Connecticut. Even so, the mistake won’t be repeated with GN at the helm, it says.

Photo: GN Store Nord / PR
by ALBERT RØNNING-ANDERSSON, translated by daniel pedersen

Hearing aid manufacturer GN Hearing is washing its hands of any culpability for a recent misleading marketing blunder in the US, which resulted in settlements between four companies and the Connecticut Office of the Attorney General.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Foto: Tyrone Siu/Reuters/Ritzau Scanpix

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

  1. Ellab slapped with customs fine over US imports
  2. China approves Y-mabs drug
  3. CEO gets "taste of own medicine" by participating in vaccine trial
  4. FDA approves Covid-19 jabs as boosters for infants
  5. Danish agency joins competition authority chorus in criticizing Oticon Medical sale
  6. FDA approves new sensor for insulin pens
  7. Full house for Ambu – all products live up to new EU requirements
  8. EU Commission proposes staggered transition to new medtech requirements after industry warnings
  9. Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
  10. New majority owner makes several board appointments at hearing firm
  11. FDA awards Pfizer's RSV vaccine candidate priority review status
  12. More countries back EU Commission investigation into potential Oticon sale
  13. Nobel Prize winner: "Good research is driven by curiosity"
  14. Forward Pharma's last hope in protracted Biogen battle extinguished
  15. FDA ruling to trigger royalty payments for Novo Nordisk

See all

Job

See all jobs

See all jobs